Healthcare Agentic AI Faces a Lifecycle Governance Gap: UALM Framework Proposes Five-Layer Architecture and KPI-Linked Thresholds

What happened

Why it matters

• ·Regulatory exposure: Healthcare AI deployments that include multi-agent architectures may not satisfy FDA SaMD predetermined change control plan requirements or EU AI Act high-risk system obligations if governance documentation addresses only single models rather than agent interaction chains.
• ·Operational impact: The Monte Carlo simulation results provide a defensible, quantitative basis for setting human escalation thresholds and kill-switch trigger conditions, which many healthcare compliance programs currently define only in qualitative or aspirational terms.
• ·Organizational risk: Without agent-specific lifecycle controls, health systems face undetected autonomy expansion, where interacting agents accumulate effective permissions or decision scope beyond what any single approval gate authorized, creating patient safety and liability exposure that standard model risk management will not surface.

Governance controls affected

What to do now

• ☐Audit your current AI model governance documentation to determine whether it explicitly covers multi-agent interaction chains or only single-model pipelines, and flag any clinical agentic deployments operating under single-model assumptions.
• ☐Map the UALM five-layer architecture against your existing agent controls (identity, task scope, trust hierarchy, human oversight gates, retirement) to identify which layers lack defined procedures or ownership.
• ☐Define quantitative KPI-linked thresholds for agent performance and autonomy boundaries, using the Monte Carlo simulation methodology in the paper as a template for stress-testing those thresholds under adverse operating assumptions.
• ☐Review your Clinical AI Governance Committee charter (SCT-002) to confirm it has explicit scope over multi-agent systems and the authority to approve or suspend agentic configurations, not only individual models.
• ☐Assess whether your inter-agent trust hierarchy documentation (AGT-003) captures delegation chains, permission inheritance, and escalation paths in a format that would satisfy an FDA inspection or EU AI Act conformity assessment.

What to watch next

Healthcare organizations should monitor the FDA's evolving predetermined change control plan guidance for signals that multi-agent system updates will require separate pre-notification rather than being absorbed within a single SaMD submission. The EU AI Act's high-risk classification for certain clinical decision support systems will begin to bite operationally through 2026 and 2027, and enforcement guidance from the EU AI Office is expected to address agentic deployments more explicitly as the market matures. Sector-specific extensions to ISO 42001 for healthcare agentic AI are also likely to emerge from standards bodies in the next 12 to 18 months, and compliance teams that have already benchmarked against the UALM maturity model will be better positioned to adopt those extensions without full program rebuilds.